Bicara Therapeutics (BCAX) Operating Expenses (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Operating Expenses of $60.2 million for Q1 2026, up 44.16% year-over-year from $41.8 million in Q1 2025, and up 46.5% quarter-over-quarter from $41.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Operating Expenses (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $60.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 44.16% year-over-year to $60.2 million; the TTM figure through Mar 2026 stood at $174.1 million (up 59.98% YoY), while the FY2025 annual figure was $155.6 million, up 88.87% from the prior year.
- Operating Expenses for Q1 2026 stood at $60.2 million, up from $41.1 million in the prior quarter.
- The five-year high for Operating Expenses was $60.2 million in Q1 2026, with the low at $9.5 million in Q3 2023.
- The 4-year median for Operating Expenses is $26.6 million (2024), against an average of $29.2 million.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 171.81% in 2025, then soared 44.16% in 2026.
- Bicara Therapeutics' Operating Expenses stood at $13.7 million in 2023, then jumped by 94.62% to $26.6 million in 2024, then soared by 54.38% to $41.1 million in 2025, then soared by 46.5% to $60.2 million in 2026.
- Business Quant data shows BCAX's Operating Expenses at $60.2 million in Q1 2026, $41.1 million in Q4 2025, and $40.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 59.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.95 Mn |
| Mar 31, 2026 | 60.24 Mn |
| Dec 31, 2025 | 41.12 Mn |
| Sep 30, 2025 | 40.68 Mn |
| Jun 30, 2025 | 32.02 Mn |
| Mar 31, 2025 | 41.79 Mn |
| Dec 31, 2024 | 26.64 Mn |
| Sep 30, 2024 | 20.63 Mn |
| Jun 30, 2024 | 19.75 Mn |
| Mar 31, 2024 | 15.37 Mn |
| Dec 31, 2023 | 13.69 Mn |
| Sep 30, 2023 | 9.53 Mn |